Hims & Hers 推出注射剂与口服 TRT,称为旗下最大男性健康发布,但无收入/订单增量

Hims Expands Testosterone Care with Injectable and Oral TRT
An estimated 20 million men
1,2
in the U.S. are affected by low testosterone, which, when left untreated, can lead to feelings of lower energy, reduced muscle mass, lower sex drive, and erectile dysfunction. For years, stigma kept many men quiet about these symptoms, but new research suggests men are starting to open up. A new survey commissioned by Hims of 2,000 U.S. men ages 18 and older found that men are speaking more openly about testosterone, and the hormonal shifts that come with age. When asked about what they actually want, 79% of men surveyed say more energy is a higher priority than more muscle,
3
so they can show up more fully at work, in their hobbies and with the people who matter most. Despite this progress, awareness of treatment hasn’t caught up: the same study shows fewer than half of men surveyed (45%) say they're familiar with specific low T treatments.
4
Starting today, Hims is closing that gap, providing eligible customers access to three new treatment options, including:
Two injectable options:
The compounded product is a twice-weekly subcutaneous injection available for eligible patients, and it's proven to increase testosterone levels within days.*
The commercial product is a generic testosterone cypionate, taken once a week via intramuscular injection, and can raise T levels in under 24 hours.**
An oral TRT option
— Kyzatrex®, is FDA-approved and has been shown to help up to 96% of men reach normal testosterone levels in just 90 days, with no injections required.***
“Good testosterone care starts with a strong relationship between a customer and their provider,” said Mike Chi, Chief Operating Officer at Hims & Hers. “Everything we’ve developed, from at-home testing and follow-up labs to ongoing provider support, is designed to make that relationship easier to start and sustain. With injectable and oral TRT, more men can start, and stay on track, with support at every step.”
These new options build on Hims’ existing
Testosterone Rx+
treatment, which includes enclomiphene, an ingredient shown to double testosterone levels
^
by boosting the body’s natural hormone production. Since introducing its testosterone offering, Hims has focused on reaching the many men living with low T, building an experience around at-home blood collection and provider-guided treatment that adapts over time. That approach is resonating. As of the second quarter, testosterone was scaling faster than any specialty outside of weight loss, just three quarters after its launch.
%
“Different men need different care approaches, from encouraging the body's own testosterone production to replacing testosterone directly," said Pete Stahl, MD, SVP of Men's Health. "Our full set of treatment options gives our partnered clinicians more ways to deliver personalized, proactive care for testosterone deficiency to our customers.”
Many men with low testosterone go undiagnosed, often because getting tested has traditionally meant booking an appointment, going to a lab, and raising a sensitive topic in person. Hims built its diagnostic experience to remove those barriers, with clinical rigor at every step. Every customer begins with a detailed medical intake that assesses symptoms and screens for risk factors. Customers then collect a blood sample at home with a
simple-to-use Tasso® device
, an FDA-cleared, push-button collector worn on the upper arm, with no lab visit or venous draw required. From that single, small sample, Hims’ lab
x
tests 22 biomarkers, including total and free testosterone, SHBG, an advanced lipid panel, and glycemic markers, giving providers a far fuller picture of a man’s health than a standalone testosterone test. A licensed provider reviews symptoms, health history, and lab results in a live visit, and treatment is only prescribed when it’s medically appropriate. For those who begin treatment, ongoing assessments, follow-up lab testing, and continued access to a support team helps providers track progress and adjust care over time.
For more information, visit
https://www.hims.com/testosterone
.
About Hims & Hers Health, Inc.
Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit
www.hims.com
and
www.forhers.com
.
Cautionary Note Regarding Forward-Looking Statements
This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “over time,” “coming,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, the launch and availability of injectable and oral testosterone replacement therapy offerings on the Hims & Hers platform, including their expected clinical effects, and the potential effects of these offerings and our broader men’s health program on customer outcomes and our business. These statements are based on management’s current expectations, but actual results may differ materially due to various factors.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the timing and logistical considerations related to the rollout of our testosterone treatment options, and the related customer adoption and response; the safety, efficacy, and clinical outcomes of testosterone therapies, including compounded and commercially available products; changes in the application, interpretation, and enforcement of healthcare, drug compounding, telehealth, controlled substance, and consumer protection laws or regulations applicable to our business; and our ability to maintain the supply, quality, and availability of the products and services underlying these offerings, and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of October 21, 2026. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.
Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA.
Not available in all 50 states. Labs and prescription required. Testosterone by Hims is a holistic program that includes lab testing, ongoing clinical support, technological tools, and medication prescribed based on what your provider determines is medically appropriate and necessary for you. See website for full details, important safety information, and restrictions. Kyzatrex® is a registered trademark of Marius Pharmaceuticals, Inc. Tasso®, Tasso+® and the Tasso® logo are trademarks of Tasso Inc. Hims, Inc. is not affiliated with or endorsed by Marius Pharmaceuticals, Inc. or Tasso Inc. © 2026 Hims & Hers Health, Inc.
ˣ Lab tests are ordered by a healthcare provider and processed in a CLIA-certified lab. They do not diagnose conditions. Review results with your provider. Not available in Hawaii. Eligibility and provider order required. Insights and action plans include recommendations that encourage you to take action that may help improve your health. Lab results alone are not intended to diagnose, treat, or cure any condition. A provider will reach out about critical results and plans include access to 24/7 provider messaging.
%
As of Q2, 2026
Citations:
1
Mulligan, T., Frick, M. F., Zuraw, Q. C., Stemhagen, A., & McWhirter, C. (2006). Prevalence of hypogonadism in males aged at least 45 years: the HIM study. International journal of clinical practice, 60(7), 762–769.
https://doi.org/10.1111/j.1742-1241.2006.00992.x
2
National Population by Characteristics: 2020-2022. Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States: April 1, 2020 to July 1, 2022 (NC-EST2022-SYAEXN). U.S. Census Bureau.
https://www.census.gov/data/tables/time-series/demo/popest/2020s-national-detail.html
. Accessed 8/11/23
3
Based on August 2026 external survey data of 2,000 U.S. men ages 18+. Respondents were asked which they prioritize more in their life: more energy or more muscle. The research was commissioned by Hims & Hers Health, Inc. and conducted by Culture Co-op.
4
Based on August 2026 external survey data of 2,000 U.S. men ages 18+. 45% selected at least one of seven listed low testosterone treatments they were familiar with. The research was commissioned by Hims & Hers Health, Inc. and conducted by Culture Co-op.
* National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 441404, Testosterone Cypionate.
https://pubchem.ncbi.nlm.nih.gov/compound/Testosterone-Cypionate
** Schulte-Beerbühl, M., & Nieschlag, E. (1980). Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate or testosterone cypionate. Fertility and sterility, 33(2), 201–203.
https://www.sciencedirect.com/science/article/pii/S0015028216445437
*** Bernstein, J. S., & Dhingra, O. P. (2024). A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product. Therapeutic advances in urology, 16, 17562872241241864.
https://doi.org/10.1177/17562872241241864
^
Thomas, J., Suarez Arbelaez, M. C., Narasimman, M., Weber, A. R., Blachman-Braun, R., White, J. T., Ledesma, B., Ghomeshi, A., Jara-Palacios, M. A., & Ramasamy, R. (2023). Efficacy of Clomiphene Citrate Versus Enclomiphene Citrate for Male Infertility Treatment: A Retrospective Study. Cureus, 15(7), e41476.
https://doi.org/10.7759/cureus.41476
Media Relations
Bjorn Trowery
Press@forhims.com
Source: Hims & Hers